US Patent

US12370179 — Methods for treating hypertrophic cardiomyopathy

Method of Use · Assigned to Cytokinetics Inc · Expires 2042-07-15 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

Methods for treating obstructive hypertrophic cardiomyopathy involve administering a cardiac myosin inhibitor, CK-3773274, and adjusting the dose based on echocardiogram results.

USPTO Abstract

Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4371 —
U-4371 —
U-4371 —
U-4371 —

Patent Metadata

Patent number
US12370179
Jurisdiction
US
Classification
Method of Use
Expires
2042-07-15
Drug substance claim
No
Drug product claim
No
Assignee
Cytokinetics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.